TOKYOMEDIJAPAN MEDICAL REFERENCE
⌕ Search databaseOfficial source · PMDA / MHLW
Rx · Reference only · no online purchase

Rybelsus (Semaglutide)

Rybelsus / Semaglutide. This Rybelsus oral-tablet record is for type 2 diabetes. This page uses a representative Japanese product as the reference entry; other products or dosage forms may exist for the same ingredient.

PMDAproduct-level source2026-05label updated2026-10-05site verified
リベルサス錠3mg/7mg/14mg · 3 mg / 7 mg
Japanese product photo · 3 mg / 7 mg · Windshear / CC BY-SA 4.0
Main useThis Rybelsus oral-tablet record is for type 2 diabetes.A brief overview of Japanese approved uses. Check the PMDA label below for product-specific conditions.
Japan product name
リベルサス錠3mg/7mg/14mg
Brand
Rybelsus
Generic name
Semaglutide
Japanese generic name
セマグルチド
Chinese name
司美格鲁肽
Marketing authorization holder
ノボ ノルディスク ファーマ株式会社
Strengths
3 mg / 7 mg / 14 mg
Dosage form
oral tablet
Therapeutic area
Metabolic
Regulatory status
Rx
Label updated
2026-05
TOKYO MEDI verified
2026-10-05
Other Japanese products with the same ingredient

オゼンピック皮下注2mg · ウゴービ皮下注(複数規格)

This page uses a representative Japanese product as the reference entry; other products or dosage forms may exist for the same ingredient.

MEDICINE REFERENCE

Detailed product reference

Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.

01

Product overview

This is oral Rybelsus for type 2 diabetes, distinct from Ozempic/Wegovy injectable products.

Read source section ↗
02

Mechanism of action

GLP-1 receptor activation affects glucose-dependent insulin/glucagon regulation and gastric emptying; the oral formulation has specific absorption requirements.

Read source section ↗
03

Japanese indications & eligibility

Japanese approval for these oral tablets is type 2 diabetes; injectable obesity indications and doses are separate.

Read source section ↗
04

Administration & dose differences

Start 3 mg daily, then 7 mg after at least four weeks; 14 mg may follow. Take fasting with ≤120 mL water; wait ≥30 minutes.

Read source section ↗
05

Adverse effects & key risks

GI effects are common; assess pancreatitis, gallbladder disease, dehydration and combination-related hypoglycemia.

Read source section ↗
06

Contraindications & special populations

Contraindications include hypersensitivity, type 1 diabetes, diabetic ketoacidosis/coma and specified acute severe illness.

Read source section ↗
07

Drug interactions

Review insulin/sulfonylureas and oral medicines such as levothyroxine affected by absorption changes.

Read source section ↗
08

Assessment & monitoring

Follow glycemic control, weight, GI symptoms, hydration and correct administration.

Read source section ↗
09

Storage & handling

Store at room temperature in the PTP blister because tablets are moisture- and light-sensitive.

Read source section ↗
10

Sources & verification

Product checked ·

Official source

These links go directly to PMDA records for this Japanese product. Professional and patient-facing sources are separated.